IN8bio, Inc.

NASDAQ:INAB

0.26 (USD) • At close December 31, 2024
Bedrijfsnaam IN8bio, Inc.
Symbool INAB
Munteenheid USD
Prijs 0.257
Beurswaarde 18,642,679
Dividendpercentage 0%
52-weken bereik 0.217 - 1.93
Industrie Biotechnology
Sector Healthcare
CEO Mr. Tai-Wei Ho
Website https://in8bio.com

An error occurred while fetching data.

Over IN8bio, Inc.

IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma

Vergelijkbare Aandelen

Spero Therapeutics, Inc. logo

Spero Therapeutics, Inc.

SPRO

1.03 USD

Neoleukin Therapeutics, Inc. logo

Neoleukin Therapeutics, Inc.

NLTX

3.49 USD

Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.

COCP

2.02 USD

Ocuphire Pharma, Inc. logo

Ocuphire Pharma, Inc.

OCUP

1.17 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)